Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: candesartan cilexetil; hydrochlorothiazide

« Back to Dashboard
Candesartan cilexetil; hydrochlorothiazide is the generic ingredient in two branded drugs marketed by Astrazeneca, Apotex Inc, Dr Reddys Labs Ltd, Macleods Pharms Ltd, and Mylan Labs, and is included in five NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has twenty-one patent family members in ten countries.

There are twenty-one drug master file entries for candesartan cilexetil; hydrochlorothiazide. Four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: candesartan cilexetil; hydrochlorothiazide

Tradenames:2
Patents:1
Applicants:5
NDAs:5
Drug Master File Entries: see list21
Suppliers / Packaging: see list12
Formulation / Manufacturing:see details

Pharmacology for Ingredient: candesartan cilexetil; hydrochlorothiazide

Tentative approvals for CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL16MG; 12.5MG
<disabled><disabled>TABLET; ORAL32MG; 12.5MG
<disabled><disabled>TABLET; ORAL32MG; 25MG

Clinical Trials for: candesartan cilexetil; hydrochlorothiazide

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Status: Completed Condition: Hypertension

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Status: Completed Condition: Hypertension

Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
Status: Completed Condition: Hypertension

Candesartan Effect in Second Stage Arterial Hypertension
Status: Completed Condition: Stage II Hypertension

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
Status: Completed Condition: Hypertension

Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo
Status: Completed Condition: Hypertension; Obesity

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Labs
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL090704-002Dec 4, 2012RXNo<disabled><disabled>
Apotex Inc
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL202884-001Dec 4, 2012RXNo<disabled><disabled>
Dr Reddys Labs Ltd
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL202965-001Jun 3, 2013RXNo<disabled><disabled>
Mylan Labs
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL090704-003Dec 4, 2012RXNo<disabled><disabled>
Macleods Pharms Ltd
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil; hydrochlorothiazide
TABLET;ORAL204100-001Feb 27, 2015RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: candesartan cilexetil; hydrochlorothiazide

Country Document Number Publication Date
European Patent Office1306088Sep 05, 2007
European Patent Office0628313Dec 14, 1994
Canada2125251Apr 26, 2005
Austria239471May 15, 2003
Germany69432644Nov 27, 2003
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc